Drug intelligence / Profile preview

ZINC02886919

Development stage: Preclinical
Lead developer: University of Texas MD Anderson Cancer Center
Modality: Small Molecules

Overview

ZINC02886919 is a small molecule inhibitor of GD3 synthase (ST8SIA1), an enzyme that regulates GD2 biosynthesis and is highly expressed in breast cancer stem-like cells (BCSCs) in triple-negative breast cancer (TNBC). By inhibiting ST8SIA1 activity, ZINC02886919 decreases the percentage of GD2+ BCSCs and suppresses mammosphere and soft agar colony formation in vitro. It is being investigated for its potential to inhibit BCSC function, tumor growth, and metastasis in TNBC.

Targets

Glycosylation (Glycosylation enzymes)

Beyond the preview

Go deeper on ZINC02886919.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZINC02886919.

Explore the full profile